Gallium maltolate Clinical Trials (2026): 5 Studies for Glioblastoma & Bladder Neoplasms
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
5 Gallium maltolate clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 3 indications (including Glioblastoma & Bladder Neoplasms) and 49 total planned enrollment. 2 Gallium maltolate clinical trials are actively recruiting. Most recent activity: NCT07331064 (May 2031).
Gallium maltolate clinical trials at a glance: phase × recruitment status
| Phase | active not recruiting | terminated | not yet recruiting | available | Total |
|---|---|---|---|---|---|
| Early P1 | 1 | 1 | |||
| P1 | 1 | 1 | 2 | ||
| P1/P2 | 1 | 1 | |||
| N/A | 1 | 1 |
Recruiting Gallium maltolate clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07331064 | GABRIELGallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor | P1 | High Grade Gliomas | 15 | May 2026 |
| NCT07515924 | Oral Gallium Maltolate for Recurrent Glioblastoma | Early P1 | Glioblastoma | 8 | Jun 2026 |
Gallium maltolate clinical trials by indication
Glioblastoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07515924 | — | Early P1 | not yet recruiting | Oral Gallium Maltolate for Recurrent Glioblastoma |
| NCT04319276 | — | P1 | active not recruiting | Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma |
| NCT06404034 | — | N/A | available | Expanded Access to Gallium Maltolate (GaM) |
High Grade Gliomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07331064 | GABRIEL | P1 | not yet recruiting | Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor |
Prostatic Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00050687 | — | P1/P2 | terminated | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies |
Terminated and withdrawn Gallium maltolate trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT00050687terminatedSafety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies
All Gallium maltolate trials (5)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07331064 | GABRIEL | Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor | P1 | not yet recruiting | 15 | Sarah Rumler | May 2026 |
| NCT07515924 | Oral Gallium Maltolate for Recurrent Glioblastoma | Early P1 | not yet recruiting | 8 | Medical College of Wisconsin | Jun 2026 | |
| NCT04319276 | Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma | P1 | active not recruiting | 26 | Medical College of Wisconsin | Nov 2022 | |
| NCT06404034 | Expanded Access to Gallium Maltolate (GaM) | — | available | 0 | Imaging Biometrics, LLC | — | |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | P1/P2 | terminated | 0 | Titan Pharmaceuticals | Jun 2001 |
Gallium maltolate clinical trials: frequently asked questions
- How many Gallium maltolate clinical trials are there?
- 5 Gallium maltolate clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov.
- Are Gallium maltolate clinical trials recruiting in 2026?
- No active Gallium maltolate trials are recruiting on ClinicalTrials.gov as of the current AACT refresh. Trials may resume; this page is updated daily.
- What conditions is Gallium maltolate being studied for?
- Gallium maltolate is being studied for Glioblastoma, Bladder Neoplasms, Diffuse Intrinsic Pontine Gliomas (DIPG), Diffuse Midline Glioma, DIPG and 7 more. The trials are grouped by indication on this page.
- What phase is Gallium maltolate in?
- Gallium maltolate clinical trials span 2 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Gallium maltolate clinical trials?
- The lead sponsor across the most Gallium maltolate trials is Medical College of Wisconsin, with 3 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Gallium maltolateas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: